GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (STU:L1PA) » Definitions » Financial Strength

Lee's Pharmaceutical Holdings (STU:L1PA) Financial Strength : 7 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lee's Pharmaceutical Holdings Financial Strength?

Lee's Pharmaceutical Holdings has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Lee's Pharmaceutical Holdings's Interest Coverage for the quarter that ended in Dec. 2024 was 5.77. Lee's Pharmaceutical Holdings's debt to revenue ratio for the quarter that ended in Dec. 2024 was 0.15. As of today, Lee's Pharmaceutical Holdings's Altman Z-Score is 3.08.


Competitive Comparison of Lee's Pharmaceutical Holdings's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Financial Strength distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Financial Strength falls into.


;
;

Lee's Pharmaceutical Holdings Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Lee's Pharmaceutical Holdings's Interest Expense for the months ended in Dec. 2024 was €-0.9 Mil. Its Operating Income for the months ended in Dec. 2024 was €5.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €8.5 Mil.

Lee's Pharmaceutical Holdings's Interest Coverage for the quarter that ended in Dec. 2024 is

Interest Coverage=-1*Operating Income (Q: Dec. 2024 )/Interest Expense (Q: Dec. 2024 )
=-1*4.983/-0.864
=5.77

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Lee's Pharmaceutical Holdings's Debt to Revenue Ratio for the quarter that ended in Dec. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(19.381 + 8.543) / 182.224
=0.15

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Lee's Pharmaceutical Holdings has a Z-score of 3.08, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 3.08 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings  (STU:L1PA) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Lee's Pharmaceutical Holdings has the Financial Strength Rank of 7.


Lee's Pharmaceutical Holdings Financial Strength Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines